The in vitro biosynthesis of metallothionein (MT) has been investigated in
RBC precursors from human cord blood in order to support the hypothesis for
the nucleated precursor origin of MT in human red blood cells (RBC). Human
RBC precursors are obtained by (i) separating glycophorin A(+) (gly A(+))
cells using a magnetic cell sorting (MACS) technique and by (ii) ex vivo ex
pansion of precursors BFU-E (burst forming unit-erythroid) on methylcellulo
se semi-solid culture media from mononuclear cells of cord blood. Biosynthe
sis of MT is detected at the protein level, by immunohistochemical staining
using a mouse monoclonal antibody (E9) in ex vivo expanded RBC precursors
obtained from BFU-E. Expression of MT is also detected at the mRNA level by
MT specific reverse transcriptase polymerase chain reaction (RT-PCR) both
in ex vivo expanded precursors from BFU-E and in MACS separated gly A(+) ce
lls. In addition, the expression of the fetal form of MT, MT-0 (also known
as MT-1H) at the mRNA level in glycophorin A(+) cells, is also confirmed by
cDNA sequencing. With these observations, to our knowledge, MT biosynthesi
s in human erythroid precursors is reported for the first time. Moreover, t
he current findings of MT-0 expression at the mRNA level in gly A(+) RBC pr
ecursors of hCB has added one more member in the list of cells/organs like
fetal liver, human monocytes, non-neoplastic tissues of adenocarcinoma etc.
, in which the expression of the human fetal form of MT, i.e. MT-0, has als
o been reported. Copyright (C) 2000 S. Karger AG. Basel.